Journal
Leukemia
Publication Date
5-14-2020
Volume
34
Issue
12
First Page
3298
Last Page
3309
Document Type
Open Access Publication
DOI
10.1038/s41375-020-0857-2
Rights and Permissions
Mikhael, J., Richter, J., Vij, R. et al. A dose-finding Phase 2 study of single agent isatuximab (anti-CD38 mAb) in relapsed/refractory multiple myeloma. Leukemia 34, 3298–3309 (2020). doi.org/10.1038/s41375-020-0857-2 Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.
Recommended Citation
Mikhael, Joseph; Vij, Ravi; and et al, "A dose-finding Phase 2 study of single agent isatuximab (anti-CD38 mAb) in relapsed/refractory multiple myeloma." Leukemia. 34, 12. 3298 - 3309. (2020).
https://digitalcommons.wustl.edu/open_access_pubs/11730
Supplemental Figure legends
41375_2020_857_MOESM2_ESM.eps (457 kB)
Supplemental Figure 1
41375_2020_857_MOESM3_ESM.eps (75 kB)
Supplemental Figure 2
